On the other hand, several studies show that some cancer treatments may also increase MMP8 levels: Increased expression of proangiogenic factors, including MMP8, by myeloid derived suppressor cells could contribute to resistance to Sunitinib treatment seen in some kidney cancer patients [169]. This evidence concerns the gene MMP8 and cancer.